Bijoy K Menon1, Emmad Qazi1, Vivek Nambiar1, Lydia D Foster1, Sharon D Yeatts1, David Liebeskind1, Tudor G Jovin1, Mayank Goyal1, Michael D Hill1, Thomas A Tomsick1, Joseph P Broderick1, Andrew M Demchuk2. 1. From the Calgary Stroke Program and the Department of Clinical Neurosciences (B.K.M., E.Q., V.N., M.G., M.D.H., A.M.D.), Department of Radiology (B.K.M., M.G., M.D.H., A.M.D.), University of Calgary, Calgary, Canada; Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.D.F., S.D.Y.); Department of Neurosciences, University of California, Los Angeles (D.L.); Department of Neurosciences, University of Pittsburgh Medical Center, PA (T.G.J.); Department of Community Health Sciences, University of Calgary, Calgary, Canada (M.D.H.); Department of Radiology (T.A.T.), Department of Neurology (J.P.B.), University of Cincinnati, OH; and Hotchkiss Brain Institute, Calgary, Canada (B.K.M., M.G., M.D.H., A.M.D.). 2. From the Calgary Stroke Program and the Department of Clinical Neurosciences (B.K.M., E.Q., V.N., M.G., M.D.H., A.M.D.), Department of Radiology (B.K.M., M.G., M.D.H., A.M.D.), University of Calgary, Calgary, Canada; Department of Public Health Sciences, Medical University of South Carolina, Charleston (L.D.F., S.D.Y.); Department of Neurosciences, University of California, Los Angeles (D.L.); Department of Neurosciences, University of Pittsburgh Medical Center, PA (T.G.J.); Department of Community Health Sciences, University of Calgary, Calgary, Canada (M.D.H.); Department of Radiology (T.A.T.), Department of Neurology (J.P.B.), University of Cincinnati, OH; and Hotchkiss Brain Institute, Calgary, Canada (B.K.M., M.G., M.D.H., A.M.D.). ademchuk@ucalgary.ca.
Abstract
BACKGROUND AND PURPOSE: In the Interventional Management of Stroke (IMS) III trial, we sought to demonstrate evidence of a differential treatment effect of endovascular treatment of acute ischemic stroke compared with intravenous tissue-type plasminogen activator, according to baseline collateral status measured using computed tomographic angiography. METHODS: Of 656 patients enrolled in Interventional Management of Stroke III trial, 306 had baseline computed tomographic angiography. Of these, 185 patients had M1 middle cerebral artery ± intracranial internal carotid artery occlusion, where baseline collateral status could be measured. Collateral status was assessed by consensus using 3 different ordinal scales and categorized as good, intermediate, and poor. Multivariable modeling was used to assess the effect of collateral status and treatment type on clinical outcome by modified Rankin Scale (mRS 0-2, mRS 0-1, and the ordinal mRS). RESULTS: Of 185 patients, 126 randomized toendovascular therapy (87.6% recanalized, 41.3% 90-day mRS 0-2) and 59 to intravenous tissue-type plasminogen activator only (60.5% recanalized, 30.5% 90-day mRS 0-2). In multivariable modeling, collateral status was a significant predictor of all clinical outcomes (P<0.05). Maximal benefit with endovascular treatment across all clinical outcomes was seen in patients with intermediate collaterals, some benefit in patients with good collaterals, and none in patients with poor collaterals, although small sample size limited the power of the analysis to show a statistically significant interaction between collateral status and treatment type (P>0.05). CONCLUSION: Using data from a large randomized controlled trial (IMS III), we show that baseline computed tomographic angiography collaterals are a robust determinant of final clinical outcome and could be used to select patients for endovascular therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov/ct2/show/. Unique identifier: 0020NCT00359424.
RCT Entities:
BACKGROUND AND PURPOSE: In the Interventional Management of Stroke (IMS) III trial, we sought to demonstrate evidence of a differential treatment effect of endovascular treatment of acute ischemic stroke compared with intravenous tissue-type plasminogen activator, according to baseline collateral status measured using computed tomographic angiography. METHODS: Of 656 patients enrolled in Interventional Management of Stroke III trial, 306 had baseline computed tomographic angiography. Of these, 185 patients had M1 middle cerebral artery ± intracranial internal carotid artery occlusion, where baseline collateral status could be measured. Collateral status was assessed by consensus using 3 different ordinal scales and categorized as good, intermediate, and poor. Multivariable modeling was used to assess the effect of collateral status and treatment type on clinical outcome by modified Rankin Scale (mRS 0-2, mRS 0-1, and the ordinal mRS). RESULTS: Of 185 patients, 126 randomized to endovascular therapy (87.6% recanalized, 41.3% 90-day mRS 0-2) and 59 to intravenous tissue-type plasminogen activator only (60.5% recanalized, 30.5% 90-day mRS 0-2). In multivariable modeling, collateral status was a significant predictor of all clinical outcomes (P<0.05). Maximal benefit with endovascular treatment across all clinical outcomes was seen in patients with intermediate collaterals, some benefit in patients with good collaterals, and none in patients with poor collaterals, although small sample size limited the power of the analysis to show a statistically significant interaction between collateral status and treatment type (P>0.05). CONCLUSION: Using data from a large randomized controlled trial (IMS III), we show that baseline computed tomographic angiography collaterals are a robust determinant of final clinical outcome and could be used to select patients for endovascular therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov/ct2/show/. Unique identifier: 0020NCT00359424.
Authors: Ferdinand Miteff; Christopher R Levi; Grant A Bateman; Neil Spratt; Patrick McElduff; Mark W Parsons Journal: Brain Date: 2009-06-09 Impact factor: 13.501
Authors: Oh Young Bang; Jeffrey L Saver; Suk Jae Kim; Gyeong-Moon Kim; Chin-Sang Chung; Bruce Ovbiagele; Kwang Ho Lee; David S Liebeskind Journal: Stroke Date: 2011-01-13 Impact factor: 7.914
Authors: Jessica C Tan; William P Dillon; Songling Liu; Felix Adler; Wade S Smith; Max Wintermark Journal: Ann Neurol Date: 2007-06 Impact factor: 10.422
Authors: Fabricio O Lima; Karen L Furie; Gisele S Silva; Michael H Lev; Erica C S Camargo; Aneesh B Singhal; Gordon J Harris; Elkan F Halpern; Walter J Koroshetz; Wade S Smith; Albert J Yoo; Raul G Nogueira Journal: Stroke Date: 2010-09-09 Impact factor: 7.914
Authors: Michael Mlynash; Maarten G Lansberg; Deidre A De Silva; Jun Lee; Soren Christensen; Matus Straka; Bruce C V Campbell; Roland Bammer; Jean-Marc Olivot; Patricia Desmond; Geoffrey A Donnan; Stephen M Davis; Gregory W Albers Journal: Stroke Date: 2011-04-07 Impact factor: 7.914
Authors: Matthew B Maas; Michael H Lev; Hakan Ay; Aneesh B Singhal; David M Greer; Wade S Smith; Gordon J Harris; Elkan Halpern; André Kemmling; Walter J Koroshetz; Karen L Furie Journal: Stroke Date: 2009-07-09 Impact factor: 7.914
Authors: Mark W Parsons; Soren Christensen; Patrick McElduff; Christopher R Levi; Ken S Butcher; Deidre A De Silva; Martin Ebinger; P Alan Barber; Christopher Bladin; Geoffrey A Donnan; Stephen M Davis Journal: J Cereb Blood Flow Metab Date: 2010-01-20 Impact factor: 6.200
Authors: Achala Vagal; Bijoy K Menon; Lydia D Foster; Anthony Livorine; Sharon D Yeatts; Emmad Qazi; Chris d'Esterre; Junzi Shi; Andrew M Demchuk; Michael D Hill; David S Liebeskind; Thomas Tomsick; Mayank Goyal Journal: Stroke Date: 2015-12-10 Impact factor: 7.914
Authors: Anna Mm Boers; Ivo Gh Jansen; Olvert A Berkhemer; Albert J Yoo; Hester F Lingsma; Cornelis H Slump; Yvo Bwem Roos; Robert J van Oostenbrugge; Diederik Wj Dippel; Aad van der Lugt; Wim H van Zwam; Henk A Marquering; Charles Blm Majoie Journal: J Cereb Blood Flow Metab Date: 2016-11-19 Impact factor: 6.200
Authors: Danielle Byrne; John P Walsh; Gavin Sugrue; Emma Stanley; Michael Marnane; Cathal D Walsh; Peter Kelly; Sean Murphy; Eoin C Kavanagh; Peter J MacMahon Journal: Eur Radiol Date: 2017-11-13 Impact factor: 5.315
Authors: I G H Jansen; O A Berkhemer; A J Yoo; J A Vos; G J Lycklama À Nijeholt; M E S Sprengers; W H van Zwam; W J Schonewille; J Boiten; M A A van Walderveen; R J van Oostenbrugge; A van der Lugt; H A Marquering; C B L M Majoie Journal: AJNR Am J Neuroradiol Date: 2016-07-14 Impact factor: 3.825
Authors: Arne Potreck; Fatih Seker; Angelika Hoffmann; Johannes Pfaff; Simon Nagel; Martin Bendszus; Sabine Heiland; Mirko Pham Journal: Eur Radiol Date: 2016-05-24 Impact factor: 5.315